Advertisement
Screener

PASSAGE BIO, INC. (PASG) Return on Tangible Equity

2.8 / 5 stars · 68/120 Roast Me

Passage BIO, Inc. Return Tang Equity

Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • Passage BIO, Inc. return tang equity for the quarter ending 2026-06-30 was -810.41%, a change of -661.80% year-over-year.
  • Passage BIO, Inc. return tang equity for the quarter ending 2026-03-31 was -320.59%, a change of -184.72% year-over-year.
  • Passage BIO, Inc. return tang equity for the quarter ending 2025-12-31 was -242.72%, a change of -137.00% year-over-year.
  • Passage BIO, Inc. return tang equity for the quarter ending 2025-09-30 was -145.45%, a change of -50.84% year-over-year.
  • Passage BIO, Inc. return tang equity for fiscal 2025 was -242.72%, a change of -137.00% from fiscal 2024.
  • Passage BIO, Inc. return tang equity for fiscal 2024 was -105.72%, a change of -14.01% from fiscal 2023.
  • Passage BIO, Inc. return tang equity for fiscal 2023 was -91.71%, a change of -24.11% from fiscal 2022.
  • Passage BIO, Inc. return tang equity for fiscal 2022 was -67.60%, a change of -9.42% from fiscal 2021.
Available history
2019-12-31 to 2026-06-30
Data captured

Historical Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2026-06-30-810.41%-$36.11M$4.46M
2026-03-31-320.59%-$37.68M$11.75M
2025-12-31-242.72%-$45.52M$18.76M
2025-09-30-145.45%-$45.26M$31.12M
2025-06-30-148.61%-$56.86M$38.26M
2025-03-31-135.87%-$63.46M$46.71M
2024-12-31-105.72%-$64.77M$61.26M
2024-09-30-94.61%-$68.8M$72.72M
2024-06-30-84.55%-$76.57M$90.56M
2024-03-31-80.50%-$84.44M$104.88M
2023-12-31-91.71%-$102.06M$111.28M
2023-09-30-88.99%-$112.38M$126.28M
2023-06-30-74.44%-$111.97M$150.41M
2023-03-31-74.93%-$127.65M$170.35M
2022-12-31-67.60%-$136.13M$201.37M
2022-09-30-71.40%-$160.21M$224.4M
2022-06-30-72.74%-$180.42M$248.05M
2022-03-31-67.30%-$189.32M$281.31M
2021-12-31-58.18%-$185.39M$318.66M
2021-09-30-47.81%-$173.18M$362.23M
2021-06-30-38.48%-$154.79M$402.27M
2021-03-31-30.24%-$133.53M$441.5M
2020-12-31-36.83%-$112.23M$304.71M
2020-09-30-25.51%-$86.44M$338.9M
2020-06-30-19.07%-$69.3M$363.4M
2020-03-31-14.37%-$55.55M$386.67M
2019-12-3181.12%-$45.63M-$56.25M

Annual Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2025-12-31-242.72%-$45.52M$18.76M
2024-12-31-105.72%-$64.77M$61.26M
2023-12-31-91.71%-$102.06M$111.28M
2022-12-31-67.60%-$136.13M$201.37M
2021-12-31-58.18%-$185.39M$318.66M
2020-12-31-36.83%-$112.23M$304.71M
2019-12-3181.12%-$45.63M-$56.25M

Similar stocks

Stock NameCountryMarket CapPE Ratio
DYADIC INTERNATIONAL INC (DYAI)United States$0.016B
BioCardia, Inc. (BCDA)United States$0.016B
Pluri Inc. (PLUR)$0.014B
INTENSITY THERAPEUTICS, INC. (INTS)United States$0.013B-1.08
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)United States$0.013B-1.05
IN8BIO, INC. (INAB)United States$0.012B-0.76
Jasper Therapeutics, Inc. (JSPR)United States$0.020B-0.37
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70
Estrella Immunopharma, Inc. (ESLA)United States$0.020B
TScan Therapeutics, Inc. (TCRX)United States$0.008B-1.23